

UNITED STATE PARTMENT OF COMMERCE Patent and Trademark Office

Addr ss: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

ATTORNEY DOCKET NO. FIRST NAMED INVENTOR APPLICATION NO. FILING DATE 09/655,710 09/05/00 KHANUJA 5 056859/0107 **EXAMINER** Γ HM12/0216 BERNHARD D. SAXE COE, S FOLEY & LARDNER PAPER NUMBER **ART UNIT** WASHINGTON HARBOUR 3000 K STREET, N.W., SUITE 500 1651 WASHINGTON DC 20007-5109 DATE MAILED: 02/16/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

	Application No.	Applicant(s)
Office Action Summary	09/655,710	KHANUJA ET AL.
	Examiner	Art Unit
	Susan Coe	1651
The MAILING DATE of this communication ap Period for Reply	ppears on the cover sheet with	the correspondence address
A SHORTENED STATUTORY PERIOD FOR REF THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a in - If NO period for reply is specified above, the maximum statutory perions - Failure to reply within the set or extended period for reply will, by stated - Any reply received by the Office later than three months after the material patent term adjustment. See 37 CFR 1.704(b). Status	N. 1.136 (a). In no event, however, may a re- reply within the statutory minimum of thirty od will apply and will expire SIX (6) MONTI tute, cause the application to become ABA	ply be timely filed (30) days will be considered timely. HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).
1) Responsive to communication(s) filed on _	•	
2a) This action is FINAL . 2b)	This action is non-final.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims		
4) Claim(s) 1-48 is/are pending in the applicat	ion.	•
4a) Of the above claim(s) is/are withdrawn from consideration.		
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claims 1-48 are subject to restriction and/o	or election requirement.	
Application Papers		
9) The specification is objected to by the Exam	niner.	
10) The drawing(s) filed on is/are objected to by the Examiner.		
11) The proposed drawing correction filed on	is: a) ☐ approved b) ☐ o	disapproved.
12) The oath or declaration is objected to by the	Examiner.	
Priority under 35 U.S.C. § 119		
13) Acknowledgment is made of a claim for fore	ign priority under 35 U.S.C. 💲	119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority docume	ents have been received.	
2. Certified copies of the priority docume	ents have been received in Ap	plication No
3. Copies of the certified copies of the papplication from the International	Bureau (PCT Rule 17.2(a)).	
* See the attached detailed Office action for a list of the certified copies not received.		
14) Acknowledgement is made of a claim for do	mestic priority under 35 U.S.C	. 9 119(e).
Attachment(s)		
15) Notice of References Cited (PTO-892) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 17) Information Disclosure Statement(s) (PTO-1449) Paper No	19) 🔲 Notice of Ir	Summary (PTO-413) Paper No(s) nformal Patent Application (PTO-152)

Application/Control Number: 09/655,710

Art Unit: 1651

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-27, drawn to a composition containing an extract from *Glycyrrhiza glabra*, classified in class 424, subclass 725.
 - II. Claims 28-48, drawn to a method of using an extract from *Glycyrrhiza glabra* to enhance the bio-availability of therapeutic substances, classified in class 424, subclass 725.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product can be used in a different process, such as the use of *Glycyrrhiza glabra* to treat bronchitis.

Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II, restriction for examination purposes as indicated is proper.

3. This application contains claims directed to the following patentably distinct species of the claimed invention:

Art Unit: 1651

A) nutraceuticals, antibiotics, anti-infective agents, or anti-cancer agents from claims 9-24, 26 32, 34-40, 42, 43, and 45;

B) side effects in claim 46.

If group I is elected, applicant is required to elected a specific species selected from A). If group II is elected, applicant is required under 35 U.S.C. 121 to elect a single disclosed species of each A) and B) for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-4, and 28-30 are generic.

A proper election would appear as follows:

Group I, species A): macrolides

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the

Page 4

examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Coe whose telephone number is (703) 306-5823. The examiner can normally be reached on Monday to Thursday from 7:30 to 5:00 and on alternating Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached on (703) 308-4743. The fax phone number for the organization where this application or proceeding is assigned is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

SDC February 13, 2001

FRANCISCO PRATS
PRIMARY EXAMINER